Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine

20260 citationsJournal Article

Authors

Burton J. Tabaac · University of Nevada, Reno

Kenneth Shinozuka · VA Palo Alto Health Care System

Anne Weisman · University of Nevada, Las Vegas

Shiven Chaudhry · University of Arizona

Mathieu Seynaeve · Beckley Foundation

Owen S. Muir · Radiall (France)

Abstract

Emerging evidence supports 5-MeO-DMT as a promising, ultra-short-acting psychedelic for treatment-resistant depression and other psychiatric conditions, warranting larger RCTs.

Topics & Keywords

Psychedelics and Drug Studies Forensic Toxicology and Drug Analysis Chemical synthesis and alkaloids

Publication Details

Published in: American Journal of Therapeutics

Volume 33, Issue 2, pp. e153-e160

DOI: 10.1097/mjt.0000000000002106

Field-Weighted Citation Impact: 0.00

Command Palette

Psychedelic Therapy: A Primer for Primary Care Clinicians—5-Methoxy-N,N-Dimethyltryptamine

Authors

Abstract

Topics & Keywords

Publication Details